PRTC Community Narratives

AnalystLowTarget's

Fair Value

Fair Value UK£4 68.5% undervalued

Reliance On Milestones And Royalties Will Create Volatility Yet Leave Long Term Upside Potential

About PRTC

Founded: 2015
Employees: 90
CEO: Robert Lyne
WebsiteView website: www.puretechhealth.com

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.

Recent PRTC News & Updates

Announcement • Apr 30

PureTech Health plc Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

PureTech Health plc has notified The Nasdaq Stock Market LLC of its intention to voluntarily delist its American Depositary Shares, each representing the right to receive ten ordinary shares of the company. Following the effectiveness of the delisting, PureTech's ordinary shares will remain listed on the London Stock Exchange (LSE), which will continue to serve as the company's primary trading venue. Following a review of the company's listing structure and shareholder trading patterns, the Board of Directors determined that maintaining a dual listing is no longer necessary. The substantial majority of trading volume, liquidity, and price discovery for PureTech's shares occurs on the London Stock Exchange, and the majority of the company's current investor base as well as the company's governance framework are centered in the United Kingdom. The cost and regulatory and administrative demands of maintaining a dual listing are significant, and concentrating trading on the London Stock Exchange will simplify governance, streamline overhead, and align the company's structure with its operational and strategic priorities. Following the delisting, and until such time as PureTech may consider terminating its American Depositary Receipt program, PureTech expects its American Depositary Shares to be quoted and traded on the over-the-counter market via a sponsored Level 1 American Depositary Receipt program. PureTech expects to file a Form 25 with the U.S. Securities and Exchange Commission relating to the delisting of its American Depositary Shares on or about May 11, 2026. The delisting is expected to become effective ten days thereafter, with the last day of trading of the company's American Depositary Shares on Nasdaq expected to be on or about May 20, 2026. Following the delisting, PureTech intends to file a Form 15F with the U.S. Securities and Exchange Commission to deregister its securities and terminate its reporting obligations under the Securities Exchange Act of 1934, as amended. Upon such filing, the company's reporting obligations with the U.S. Securities and Exchange Commission will be suspended immediately. The termination of the company's registration and reporting obligations is expected to become effective no later than 90 days after such filing if there are no objections from the U.S. Securities and Exchange Commission.

Recent updates

No updates

PureTech Health plc Stock Price

PRTC Share Price Performance

PRTC Community Narratives

Reliance On Milestones And Royalties Will Create Volatility Yet Leave Long Term Upside Potential

Reliance On Milestones And Royalties Will Create Volatility Yet Leave Long Term Upside Potential

Trending Discussion

Recently Updated Narratives

Reliance On Milestones And Royalties Will Create Volatility Yet Leave Long Term Upside Potential

Snowflake Analysis

PureTech Health plc Key Details

About PRTC

Recent PRTC News & Updates

Reliance On Milestones And Royalties Will Create Volatility Yet Leave Long Term Upside Potential

PureTech Health plc(OTCPK:PRTC.Y) dropped from NASDAQ Composite Index

PureTech Health plc Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

Recent updates

PureTech Health plc Competitors

Allergy Therapeutics

Avacta Group

Scancell Holdings